(Q47845658)

English

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

0 references

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

object named as

M Allen

3

0 references

10

object named as

S E Frey

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

author name string

P B Gilbert

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

Y-L Chiu

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

D N Lawrence

4

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

C Chapdu

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

H Israel

6

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

D Holman

7

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

M C Keefer

8

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

M Wolff

9

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

NIAID HIV Vaccine Trials Network

11

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

21

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

21-22

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

2933-2947

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

Candidate AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Human Studies in the Development of Human Immunodeficiency Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trials of HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of immunological adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900158-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0264-410X(03)00158-0

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12798637

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47845658&oldid=2172572343"